Clinical outcomes assessment in multiple sclerosis

被引:149
作者
Rudick, R
Antel, J
Confavreux, C
Cutter, G
Ellison, G
Fischer, J
Lublin, F
Miller, A
Petkau, J
Rao, S
Reingold, S
Syndulko, K
Thompson, A
Wallenberg, J
Weinshenker, B
Willoughby, E
机构
[1] MCGILL UNIV, MONTREAL NEUROL INST, MONTREAL, PQ, CANADA
[2] HOP ANTIQUAILLE, LYON, FRANCE
[3] AMC CANC INST, DENVER, CO USA
[4] UNIV CALIF LOS ANGELES, CTR MED, LOS ANGELES, CA 90024 USA
[5] THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA
[6] MAIMONIDES HOSP, BROOKLYN, NY 11219 USA
[7] UNIV BRITISH COLUMBIA, VANCOUVER, BC V5Z 1M9, CANADA
[8] MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA
[9] NATL MULTIPLE SCLEROSIS SOC, NEW YORK, NY USA
[10] VET AFFAIRS MED CTR W LOS ANGELES, LOS ANGELES, CA USA
[11] NEUROL INST, LONDON, ENGLAND
[12] BERLEX LABS INC, RICHMOND, CA USA
[13] MAYO CLIN, ROCHESTER, MN USA
[14] AUKLAND HOSP, AUCKLAND, NEW ZEALAND
关键词
D O I
10.1002/ana.410400321
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This article represents initial deliberation of an international task force appointed by the US National Multiple Sclerosis Society to develop recommendations for optimal clinical assessment tools for multiple sclerosis clinical trials. Presented within this article are the key issues identified by the task force during its initial year of deliberation. These include the precise purpose for a clinical assessment tool, the clinical dimensions to be measured in a multidimensional outcome measure, desirable attributes of an optimal clinical outcome measure, the complexities af multidimensional outcome measures, the relative merits of categorical clinical ratings and quantitative functional assessments, and a number of other important design issues that relate to the use of a multidimensional outcome measure. An action plan for analysis of existing data is summarized, as are the plans for more detailed recommendations front the task force.
引用
收藏
页码:469 / 479
页数:11
相关论文
共 47 条
  • [1] ALBERT MS, 1991, HDB CLIN TRIALS NEUR, P131
  • [2] ANDERSON JJ, 1993, J RHEUMATOL, V20, P535
  • [3] [Anonymous], 1980, International classification of impairments, disabilities and handicaps
  • [4] BELENDIUK G, 1989, QUANTIFYING NEUROLOG, P177
  • [5] Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences, V2
  • [6] METHODOLOGICAL AND STATISTICAL PROBLEMS IN THE CONSTRUCTION OF COMPOSITE MEASUREMENT SCALES - A SURVEY OF 6 MEDICAL AND EPIDEMIOLOGIC JOURNALS
    COSTE, J
    FERMANIAN, J
    VENOT, A
    [J]. STATISTICS IN MEDICINE, 1995, 14 (04) : 331 - 345
  • [7] ASSESSING THE RESPONSIVENESS OF FUNCTIONAL SCALES TO CLINICAL-CHANGE - AN ANALOGY TO DIAGNOSTIC-TEST PERFORMANCE
    DEYO, RA
    CENTOR, RM
    [J]. JOURNAL OF CHRONIC DISEASES, 1986, 39 (11): : 897 - 906
  • [8] DIXON WJ, 1974, COMMUNITY STAT, V3, P301
  • [9] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DUQUETTE, P
    GIRARD, M
    DESPAULT, L
    DUBOIS, R
    KNOBLER, RL
    LUBLIN, FD
    KELLEY, L
    FRANCIS, GS
    LAPIERRE, Y
    ANTEL, J
    FREEDMAN, M
    HUM, S
    GREENSTEIN, JI
    MISHRA, B
    MULDOON, J
    WHITAKER, JN
    EVANS, BK
    LAYTON, B
    SIBLEY, WA
    LAGUNA, J
    KRIKAWA, J
    PATY, DW
    OGER, JJ
    KASTRUKOFF, LF
    MOORE, GRW
    HASHIMOTO, SA
    MORRISON, W
    NELSON, J
    GOODIN, DS
    MASSA, SM
    GUTTERIDGE, E
    ARNASON, BGW
    NORONHA, A
    REDER, AT
    MARTIA, R
    EBERS, GC
    RICE, GPA
    LESAUX, J
    JOHNSON, KP
    PANITCH, HS
    BEVER, CT
    CONWAY, K
    WALLENBERG, JC
    BEDELL, L
    VANDENNOORT, S
    WEINSHENKER, B
    WEISS, W
    REINGOLD, S
    PACHNER, A
    TAYLOR, W
    [J]. NEUROLOGY, 1993, 43 (04) : 655 - 661
  • [10] DESIGN STRATEGIES IN MULTIPLE-SCLEROSIS CLINICAL-TRIALS
    ELLISON, GW
    MYERS, LW
    LEAKE, BD
    MICKEY, MR
    KE, D
    SYNDULKO, K
    TOURTELLOTTE, WW
    [J]. ANNALS OF NEUROLOGY, 1994, 36 : S108 - S112